- Fletterick, Robert;
- Samaniego, CS;
- Suh, JH;
- Chattopadhyay, A;
- Olivares, K;
- Guy, N;
- Sivils, JC;
- Dey, P;
- Yumoto, F;
- Fletterick, RJ;
- Strom, AM
© 2015 Storer Samaniego et al.FKBP52 and β-catenin have emerged in recent years as attractive targets for prostate cancer treatment. β-catenin interacts directly with the androgen receptor (AR) and has been characterized as a co-Activator of AR-mediated tr
